NIH AI Restriction
NIH policy NOT-OD-25-132 prohibits the use of AI-generated text in grant applications that is not substantially modified by the applicant. All AI-drafted sections must be thoroughly rewritten in your own words before submission.
View full policyAlzheimer's Drug-Development Program (U01 Clinical Trial Optional)
About This Grant
The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose pre-clinical and early-stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that aim to prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms.
Through the NOFO, NIA is continuing the Alzheimer's Drug-Development Program (ADDP) with the aim of catalyzing drug development for AD. The ADDP is designed to provide funding support to academic and biotech researchers for preclinical drug development activities that can be conducted in their own laboratories or conducted in collaboration with contract research organizations that specialize in preclinical drug development activities. By supporting the most challenging and costly steps of drug development and seamlessly connecting preclinical drug development and first-in-human testing for drug candidates, the ADDP program seeks to:
• Continue to expand the number of investigational new drug candidates for a portfolio of emerging therapeutic targets; • Continue to expand the therapeutic pipeline for AD with drug candidates targeting multiple underlying disease mechanisms that can be used as mono-therapy or as part of combination therapy; and • Enable a precision medicine approach to AD drug development.
The NOFO will utilize the U01 activity code. Applications are not being solicited at this time. This notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
Grant Summary
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) is a National Institutes of Health grant providing funding that varies by award for nonprofit, school district, municipality. This is a forecast: it is not yet open for applications, and the estimated deadline is 2027-06-18. Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 1,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
- Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;
How to Apply
Not stated by funder
Estimated 2027-06-18
- 1Confirm your organization is eligible for Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) from National Institutes of Health, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to National Institutes of Health before the deadline.
Search & build free — $99 one-time to unlock the export-ready application pack. No subscription.
Don't want to draft it yourself?
We'll draft the complete application against National Institutes of Health's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional): Frequently Asked Questions
Who is eligible for the Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)?
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) is offered by National Institutes of Health. The listing names these applicant types: nonprofit, school district, municipality, tribal government, university, small business. It is open to organizations nationwide unless the funder specifies otherwise. The funder's eligibility section is the authority, so confirm your organization type, location, and the population or project served against it before applying.
How much funding does the Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) provide?
National Institutes of Health does not publish a set award amount for Alzheimer's Drug-Development Program (U01 Clinical Trial Optional), so award sizes vary. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs, and confirm the expected range with the funder.
When is the Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) deadline?
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) is a forecast from National Institutes of Health: it is not yet open for applications. The funder's estimated deadline is 2027-06-18, and forecast dates often change. Confirm the official posting with the funder before you prepare an application.
How do you apply for the Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)?
To apply for Alzheimer's Drug-Development Program (U01 Clinical Trial Optional), confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from National Institutes of Health.
Browse More Grants
Related Grants
State Veterans Home Construction Grant Program
Construction of State Home Facilities — up to $275M
Advancing Global Health
Bureau of Global Health Security and Diplomacy — up to $250M
Title X Family Planning Services Grants
Office of the Assistant Secretary for Health — up to $22M
Fiscal Year (FY) 2027 Service Area Competition (SAC)
Health Resources and Services Administration — up to $10.1M
Occupational Safety and Health Education and Research Centers (T42)
Centers for Disease Control and Prevention - ERA — up to $9M
Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
National Institutes of Health — up to $8M